Roche shares data from phase 3 trial of Xolair as allergy treatment
Betsy Goodfellow | February 26, 2024 | News story | Research and Development | Allergic Disorders, Roche, Xolair, allergy, clinical trial, food allergy
Roche has announced data from stage 1 of the National Institutes of Health (NIH)-sponsored phase 3 OUtMATCH trial, which assessed the safety and efficacy of Xolair (omalizumab) in patients allergic to peanuts and at least two other common foods.
The results were published in the New England Journal of Medicine (NEJM) and featured in a symposium at the 2024 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting.
The trial demonstrated that treatment with Xolair increased the amount of allergen that it took to cause moderate to severe allergic reactions in multi-food allergic people as young as one-year. The allergens included peanuts, milk, egg, wheat and tree nuts (cashew, hazelnut and walnut).
Robert Wood MD, director of the Eudowood Division of Allergy, Immunology and Rheumatology at Johns Hopkins Children’s Center, US, and principal investigator on the study, commented: “Over the past 35 years, I have seen how debilitating food allergies can be for patients and their loved ones, as they are consumed by the fear of accidental exposure. While allergic reactions to exposures are common and often severe, there have been limited treatment advancements for food allergy. The results of the OUtMATCH study showed that anti-IgE therapy could significantly reduce the occurrence of allergic reactions across multiple foods in the event of an accidental exposure.”
Betsy Goodfellow
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
